Articles tagged "Rejection"

2020 American Transplant Congress
Costimulation Blockade-Based Maintenance Immunosuppression in a Sensitized Nonhuman Primate Kidney Allotransplantation Model
R. Schmitz, Z. W. Fitch, P. M. Schroder, A. Y. Choi, M. Manook, J. Yoon, J. Kwun, S. J. Knechtle
Department of Surgery, Duke University Medical Center, Durham, NC
*Purpose: Sensitized transplant recipients represent a challenging population in part due to the presence of donor-specific antibodies (DSA), which increase the risk of antibody-mediated rejection.…
2020 American Transplant Congress
Can Cxcr3⁺Cd62l^–Cd4⁺ T Cells Serve as Early Warning Sentinels for Subclinical Rejections after Vascularized Composite Allotransplantation (vca)?
M. Kim¹, D. Fisher¹, J. Loo¹, J. Skitzki¹, E. Repasky²
¹Surgical Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, ²Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, NY
*Purpose: New microsurgical techniques and powerful immunosuppressive drugs have made it possible for severely injured patients to receive VCA to replace limbs, hands, or faces,…
2020 American Transplant Congress
Comparison of Clinical Characteristics and Outcomes of Early Antibody-Mediated Rejection and Late Antibody-Mediated Rejection after Kidney Transplantation
G. Chen, Z. Wu, C. Wang, X. Liu, Q. Li, L. Chen
Organ Transplant Center, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China
*Purpose: Antibody-mediated rejection(AMR) is a major risk factor for graft loss after kidney transplantation. Some AMR appeared within 6 months after kidney transplant, that we…
2020 American Transplant Congress
Kidney Transplant Results Comparing Two Formulations of Prolonged-Release Tacrolimus: Paired Study of Kidney Donors
V. Lopez Jimenez, J. Alonso Titos, J. Gamez España, M. Cabello Díaz, D. Hernández Marrero
Nephrology Department, Regional University Hospital, University of Malaga, IBIMA, REDinREN (RD16/0009/0006), Málaga, Spain
*Purpose: Although the formulations of prolonged-release tacrolimus (Advagraf® and Envarsus®) are effective after kidney transplantation in terms of efficacy and safety, no paired analysis has…
2020 American Transplant Congress
Dominant Negative Polymorphisms in TNFRSF13B are Associated with Poor Transplant Outcome
M. G. de Mattos-Barbosa¹, E. T. Luning Prak², E. Farkash³, J. L. Platt⁴, M. Cascalho⁴
¹Transplant Surgery, University of Michigan, Ann Arbor, MI, ²Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, ³Pathology, University of Michigan, Ann Arbor, MI, ⁴Transplant Surgery and Microbiology and Immunology, University of Michigan, Ann Arbor, MI
*Purpose: Transmembrane Activator and CAML Interactor (TACI) is a highly polymorphic receptor that controls B cell activation and differentiation into antibody-secreting cells. Allelic variants of…
2020 American Transplant Congress
Rabbit Anti-Thymocyte Globulin versus Anti-T Lymphocyte Globulin Rescue Therapies in Delayed Graft Function after Kidney Transplantation from Donors after Cardiac Death
H. Yang¹, Y. Shi², X. Li¹, C. Long¹, H. Li³, Z. Wang³
¹Department of Organ Transplantation, Jiangxi Provincial People’s Hospital Affiliated to Nanchang University, Nanchang, China, ²Department of Pathology, Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, ³Department of Urologic Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
*Purpose: Delayed graft function (DGF) is common in recipients of kidney transplants from donation after cardiac death (DCD) donors, induction therapy with monoclonal or polyclonal…
2020 American Transplant Congress
Stanford Integrated Psychosocial Assessment for Transplant Predicts Immunosuppression Non-Adherence after Liver Transplantation
S. Deutsch-Link¹, E. Weinberg², M. McDougal³, L. Jones⁴, T. Bitterman², M. Serper²
¹Medicine, University of Pennsylvania, Philadelphia, PA, ²Gastroenterology & Hepatology, University of Pennsylvania, Philadelphia, PA, ³Drexel University, Philadelphia, PA, ⁴PCOM, Philadelphia, PA
*Purpose: Patients with end-stage liver disease presenting for liver transplant (LT) evaluation have a high burden of psychosocial comorbidities. The Stanford Integrated Psychosocial Assessment for…
2020 American Transplant Congress
Donor-Derived Cell-Free DNA Levels During Early Rejection after Kidney Transplant May Be Impacted by Type of Induction Agent Received
M. Gillespie, K. Lim, A. Vo, E. Huang, N. Ammerman, A. Peng, R. Najjar, S. Sethi, S. Jordan
Cedars-Sinai, Los Angeles, CA
*Purpose: Donor-derived cell-free DNA (dd-cfDNA) is an injury biomarker that detects rejection in kidney transplant recipients (KTR). It is reported as % cfDNA from the…
2020 American Transplant Congress
Antimicrobial Prophylaxis Post Antibody Mediated Rejection Treatment in Pediatric Kidney Transplant Recipients: Interim Report from the Paramour “PediAtric Renal AMr Outcomes” Study
S. Solomon¹, R. Garro², N. Hayde³, A. Jain⁴, M. Kallash⁵, K. Twombley⁶, I. Ashoor⁷
¹Maria Fareri Children's Hospital, Valhalla, NY, ²Emory University, Atlanta, GA, ³The Children's Hospital at Montefiore, Bronx, NY, ⁴Children's Hospital of Michigan, Detroit, MI, ⁵Nationwide Children's Hospital, Columbus, OH, ⁶Medical University of South Carolina, Charleston, SC, ⁷LSU Health New Orleans, New Orleans, LA
*Purpose: Universal guidelines do not exist for post antibody mediated rejection (AMR) treatment antimicrobial prophylaxis (ppx) in pediatric kidney transplant (KT) recipients. We sought to…
2020 American Transplant Congress
First Report of Successful CD38-Antagonist Daratumumab Augmented Carfilzomib-Based Treatment of Refractory Definite AMR of the Lung Allograft
M. N. Kildea¹, C. R. Ensor¹, J. Kim¹, L. Bogar¹, D. Colella¹, R. D. Davis¹, M. Marschner¹, A. Zeevi², N. Soe¹, C. Gries¹
¹AdventHealth, Orlando, FL, ²University of Pittsburgh, Pittsburgh, PA
*Purpose: Antibody-mediated rejection (AMR) after lung transplant (LT) is associated with early progressive chronic lung allograft dysfunction (CLAD) and death. Therapeutic regimens remain poorly evaluated.…